Bryan has more than 20 years of experience in research and development, with an established record leading drug discovery teams for target identification, target engagement in translatable models of human disease and clinical candidate delivery. He co-founded Latigo. Prior to Latigo, and during his ten-year tenure at Amgen, he led multi-modality discovery programs to advance small molecule, peptide, and antibody-based therapeutics for pain and migraine indications. Bryan developed and launched a multi-species discovery effort to identify new pain target genes using genomics, bioinformatics, and genetics approaches. Prior to Amgen, Bryan was at Senomyx, a biotechnology company working on taste biology, where he led drug discovery and target identification efforts for taste receptors and transmembrane targets. Bryan has a B.S. in Animal Physiology and Neuroscience from the University of California, San Diego, a Ph.D. in Physiology from Dartmouth Medical School, and completed his postdoctoral fellowship at The Scripps Research Institute in La Jolla, California.